Applicants,Chemical_Name,Funding_requested_for,Pharmaceutical,Priority_List,Schedules,Therapeutic_group
Clinician,Cabozantanib Nivolumab,First line treatment for metastatic IMDC score intermediate and poor prognosis kidney cancer with a clear cell component.,"Cabozantanib Nivolumab (Cabometyx,cometriq Opdivo)",Only if cost neutral or cost saving,Community and Hospital,Oncology Agents and Immunosuppressants
